Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SOPH
stocks logo

SOPH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
20.49M
+15.57%
-0.255
+10.87%
20.28M
+14.05%
-0.235
-9.62%
21.09M
+15.12%
-0.253
-23.48%
Estimates Revision
The market is revising Upward the revenue expectations for SOPHiA GENETICS SA (SOPH) for FY2025, with the revenue forecasts being adjusted by 1.46% over the past three months. During the same period, the stock price has changed by 54.94%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.5%
In Past 3 Month
Stock Price
Go Up
up Image
+54.94%
In Past 3 Month
Wall Street analysts forecast SOPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOPH is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast SOPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOPH is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.020
sliders
Low
7.00
Averages
7.00
High
7.00
Current: 5.020
sliders
Low
7.00
Averages
7.00
High
7.00
BTIG
Mark Massaro
Buy
maintain
$6 -> $7
2025-11-10
Reason
BTIG
Mark Massaro
Price Target
$6 -> $7
2025-11-10
maintain
Buy
Reason
BTIG analyst Mark Massaro raised the firm's price target on Sophia Genetics to $7 from $6 and keeps a Buy rating on the shares. The company delivered a solid Q3 revenue beat and raise, and this small cap name looks well-positioned to make a big move in 2026, the analyst tells investors in a research note. Management also sees signs of a recovery building in biopharma, which when added to more clinical customers coming online at higher selling prices, will mark an inflection point in revenue and margin, the firm added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for SOPHiA GENETICS SA (SOPH.O) is -5.15, compared to its 5-year average forward P/E of -4.64. For a more detailed relative valuation and DCF analysis to assess SOPHiA GENETICS SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.64
Current PE
-5.15
Overvalued PE
-1.90
Undervalued PE
-7.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.33
Undervalued EV/EBITDA
-6.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.13
Current PS
0.00
Overvalued PS
12.21
Undervalued PS
0.05
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1033.12% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SOPH News & Events

Events Timeline

(ET)
2025-11-11
09:04:41
Sophia Genetics and Complete Genomics Collaborate on Oncology Testing Technology Integration
select
2025-11-11
08:03:51
Sophia Genetics and Element Biosciences Collaborate to Enhance Genomic Workflow Efficiency
select
2025-11-04 (ET)
2025-11-04
06:42:39
Sophia Genetics Adjusts FY25 Revenue Forecast to $75M-$77M, Up from $72M-$76M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-11PRnewswire
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

  • Collaboration Announcement: Complete Genomics and SOPHiA GENETICS have partnered to co-market MSK-ACCESS® and MSK-IMPACT® using SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform, aiming to enhance access to precision oncology testing globally.

  • Integrated Workflow: The collaboration will provide an integrated sample-to-report workflow for laboratories, combining MSK's validated assays, SOPHiA GENETICS' analytics, and Complete Genomics' sequencing technology to improve cancer genomic profiling.

  • Technological Advancements: The DNBSEQ-T1+ platform offers high accuracy and flexibility, allowing laboratories to run multiple tumor-normal sample pairs efficiently, while SOPHiA DDM™ enhances data analysis through AI.

  • Market Impact: This partnership is expected to facilitate the adoption of precision oncology solutions in clinical laboratories and cancer centers, providing a cost-effective path for comprehensive genomic profiling in research.

[object Object]
Preview
7.5
11-11PRnewswire
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine

  • Partnership Announcement: SOPHiA GENETICS and Element Biosciences have partnered to integrate AI-driven analytics with advanced sequencing technologies, aiming to enhance genomic workflows and support precision medicine research.

  • Technology Integration: The collaboration combines SOPHiA DDM™ analytics platform with Element's AVITI24™ and AVITI sequencing systems, providing a streamlined, end-to-end workflow for next-generation sequencing (NGS) that enhances speed, scalability, and flexibility.

  • Expert Insights: Leaders from both companies, including Professor Hagay Sobol and CEOs Jurgi Camblong and Molly He, emphasize the transformative potential of this partnership in delivering accurate genomic testing and democratizing access to precision medicine.

  • Company Missions: SOPHiA GENETICS focuses on expanding access to data-driven medicine through AI, while Element Biosciences aims to make high-performance genomics accessible, both contributing to advancements in research and therapeutic developments.

[object Object]
Preview
6.0
11-10Benzinga
Zscaler Expected to Surge Over 9%? Check Out 10 Leading Analyst Predictions for Monday

  • Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including Piper Sandler lowering SITE Centers' target from $12 to $10 while maintaining an Overweight rating.

  • Upgrades and Downgrades: Notable upgrades include Leerink Partners raising Eli Lilly's target from $886 to $1,104 and upgrading the stock from Market Perform to Outperform, while Stifel downgraded Trex Company from Buy to Hold, cutting its target from $61 to $35.

  • Price Target Increases: Companies like Genmab and Everspin Technologies saw their price targets increased by HC Wainwright & Co. and Needham, respectively, with Genmab's target rising from $40 to $41 and Everspin's from $8 to $10.5.

  • Significant Cuts: Rothschild & Co. significantly reduced HubSpot's price target from $610 to $450, downgrading it from Buy to Neutral, while Morgan Stanley cut Norwegian Cruise Line's target from $27 to $25, maintaining an Equal-Weight rating.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is SOPHiA GENETICS SA (SOPH) stock price today?

The current price of SOPH is 5.02 USD — it has increased 2.03 % in the last trading day.

arrow icon

What is SOPHiA GENETICS SA (SOPH)'s business?

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.

arrow icon

What is the price predicton of SOPH Stock?

Wall Street analysts forecast SOPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOPH is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is SOPHiA GENETICS SA (SOPH)'s revenue for the last quarter?

SOPHiA GENETICS SA revenue for the last quarter amounts to 19.46M USD, increased 22.77 % YoY.

arrow icon

What is SOPHiA GENETICS SA (SOPH)'s earnings per share (EPS) for the last quarter?

SOPHiA GENETICS SA. EPS for the last quarter amounts to -0.30 USD, increased 7.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for SOPHiA GENETICS SA (SOPH)'s fundamentals?

The market is revising Upward the revenue expectations for SOPHiA GENETICS SA (SOPH) for FY2025, with the revenue forecasts being adjusted by 1.46% over the past three months. During the same period, the stock price has changed by 54.94%.
arrow icon

How many employees does SOPHiA GENETICS SA (SOPH). have?

SOPHiA GENETICS SA (SOPH) has 423 emplpoyees as of December 05 2025.

arrow icon

What is SOPHiA GENETICS SA (SOPH) market cap?

Today SOPH has the market capitalization of 340.59M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free